- Home
- NAUT
as 01-21-2025 4:00pm EST
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 284.7M | IPO Year: | N/A |
| Target Price: | $3.58 | AVG Volume (30 days): | 165.9K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $3.12 | Next Earning Date: | 02-26-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Nautilus Biotechnolgy Inc. News
NAUT Breaking Stock News: Dive into NAUT Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 days ago
US Penny Stocks To Watch In January 2025
Simply Wall St.
a month ago
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks
Simply Wall St.
a month ago
With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future
Simply Wall St.
2 months ago
3 US Penny Stocks With Market Caps Up To $400M
GlobeNewswire
3 months ago
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
GlobeNewswire
3 months ago
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
GuruFocus.com
3 months ago
Nautilus Biotechnology Inc (NAUT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
GlobeNewswire
3 months ago
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
Compare NAUT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAUT Nautilus Biotechnolgy Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.